AI Summary
We reviewed 10000 live results for truxima 10mg/ml concentrate for solution for infusion and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Antineoplastic Agents and Monoclonal Antibodies.
Comparison Table
Source: Celltrion, Inc.
Description
Truxima is a monoclonal antibody and biosimilar to the reference product MabThera (rituximab). It is used as a targeted cancer therapy for Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL), as well as for treating Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), and Microscopic Polyangiitis (MPA). It is available in 100mg/10ml and 500mg/50ml single-dose vials for intravenous infusion.
Best for
Oncology patients, Rheumatoid arthritis treatment, Biosimilar cost-savings and Targeted immunotherapy
Rating
Source: AstraZeneca Malaysia
Description
Locally registered and approved formulation of Soliris available in Malaysia. This concentrate is intended for intravenous infusion in clinical settings for the treatment of rare conditions such as aHUS and PNH. It is regulated as a scheduled poison by the Malaysian National Pharmaceutical Regulatory Agency (NPRA).
Best for
Malaysian residents, hospital-based infusion, NPRA-approved prescriptions and local rare disease support
Rating
Source: Novartis (Thailand) Limited
Description
A 50 mg/ml sterile concentrate intended for intravenous infusion. It is specifically utilized in hospital settings for patients unable to take oral medication, particularly in the immediate post-operative period following a transplant.
Best for
inpatient hospital care, post-operative transplant recovery, intravenous administration and critical care immunosuppression
Rating
| Compare | Truxima 10mg/ml Concentrate for Solution for Infusion | Soliris 10mg/ml Concentrate for Solution for Infusion | Sandimmun Concentrate for Infusion |
|---|---|---|---|
| Source | Celltrion, Inc. | AstraZeneca Malaysia | Novartis (Thailand) Limited |
| Description | Truxima is a monoclonal antibody and biosimilar to the reference product MabThera (rituximab). It is used as a targeted cancer therapy for Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL), as well as for treating Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), and Microscopic Polyangiitis (MPA). It is available in 100mg/10ml and 500mg/50ml single-dose vials for intravenous infusion. | Locally registered and approved formulation of Soliris available in Malaysia. This concentrate is intended for intravenous infusion in clinical settings for the treatment of rare conditions such as aHUS and PNH. It is regulated as a scheduled poison by the Malaysian National Pharmaceutical Regulatory Agency (NPRA). | A 50 mg/ml sterile concentrate intended for intravenous infusion. It is specifically utilized in hospital settings for patients unable to take oral medication, particularly in the immediate post-operative period following a transplant. |
| Best for | Oncology patients, Rheumatoid arthritis treatment, Biosimilar cost-savings and Targeted immunotherapy | Malaysian residents, hospital-based infusion, NPRA-approved prescriptions and local rare disease support | inpatient hospital care, post-operative transplant recovery, intravenous administration and critical care immunosuppression |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Truxima 10mg/ml Concentrate for Solution for Infusion from Celltrion, Inc.."
I picked this because Truxima provides a cost-effective, high-quality biosimilar alternative to the original rituximab biologic, suitable for specialized oncology and rheumatology care.
Share this search
Related Finds